For a long time, the standard of care in mental and behavioral health has been some combination of pharmaceuticals and talk therapy. But with FDA-cleared, rigorously vetted digital health apps, there's a new piece of the puzzle, and it has the potential to combine the advantages of therapy with the scalability of drugs.

In this episode of HIMSSCast, Big Health CEO Peter Hames joins host Jonah Comstock to talk about the future of mental health and lessons learned so far.

This episode is brought to you by Carahsoft.

Talking points:

What Big Health is all about
Scalable mental health therapies
Treating algorithms and therapies like drugs
Efficacy data and safety of digital therapeutics vs drugs
How pharma companies are responding to digital therapeutics
Predicting the future of mental health care
Big Health’s partner relationships
Mental health stigma and digital therapeutics
Digital therapeutics have arrived
What’s next for Big Health?

More about this episode:

Sleep, stress app maker Big Health locks in $39M Series B raise

Big Health follows up Sleepio with Daylight, an app for anxiety

CVS Health kicks off digital health-friendly service for PBM clients with Big Health’s Sleepio

Simulation model: Big Health's Sleepio drives greater cost savings than group CBT or drug therapy

From Big Health:

Sleepio randomized controlled trial showing 76% of patients achieved remission from insomnia.
Daylight randomized controlled trial showing that 71% of patients achieved remission from clinical anxiety.
Economic evaluation of a Fortune 500 employer showing $1,677 lower annualized healthcare costs per employee.
JAMA study showing that Sleepio improves broad health outcomes including: functional health, psychological well-being, and sleep-related qualities.

Are digital therapeutics the future of mental health? — with Peter Hames

HIMSSCast